ArticleDiabetes, obesity & metabolism2026
Bifidobacterium breve BBr60 Improves Metabolic Abnormalities by Regulating Gut Microbiota Balance in a High-Fat Diet-Induced Obese Mouse Model.
Article in Diabetes, obesity & metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Bifidobacterium breve BBr60 Improves Metabolic Abnormalities by Regulating Gut Microbiota Balance in a High-Fat Diet-Induced Obese Mouse Model.Diabetes, obesity & metabolism · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
aimThis study aimed to evaluate the modulatory effects of Bifidobacterium breve BBr60 on gut microbiota dysbiosis and metabolic abnormalities in a high-fat diet (HFD) -induced obese mouse model.
methodsThirty mice aged 6 weeks were divided into a normal diet group (CTL), an HFD group, and a BBr60 intervention group (HFD + BBr60). During 8 weeks, the food intake and body weight of the mice were monitored. Subsequently, an oral glucose tolerance test (OGTT) was conducted, and fasting insulin levels, lipid profiles, and the gut microbiota composition were determined. Liver lesions, inflammation levels, and tight junction protein expression were examined using Oil Red O staining, haematoxylin and eosin staining, and reverse transcription polymerase chain reaction analysis, respectively. 16s rRNA high-throughput sequencing techniques were used to investigate the diversity and richness of the gut microbiota.
resultsBBr60 not only ameliorated HFD-induced metabolic disorders, including weight gain (body weight, p < 0.001), hyperglycaemia (FBG, p < 0.001), insulin resistance (HOMA-IR, p = 0.002), dyslipidaemia (TC, p < 0.001), and liver steatosis, but also mitigated systemic inflammation and impaired intestinal permeability. Furthermore, BBr60 reversed gut microbiota dysbiosis, as evidenced by a significant reduction in the relative abundance of opportunistic pathogens such as Duncaniella, Allobaculum, and Parasutterella while increasing beneficial bacteria such as Clostridium cluster XIVa, Limosilactobacillus, and Bifidobacterium. Time-dynamic analyses showed that BBr60 regulated the relative abundance of the gut microbiota and improved HFD-induced dysbiosis of the gut microbiota.
conclusionBBr60 significantly ameliorated glucose and lipid metabolic disorders and gut microbiota dysbiosis in an HFD-induced obese mouse model, and these effects were associated with changes in gut microbiota composition, suggesting its potential as a therapeutic intervention for obesity-related metabolic abnormalities.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.